SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Clene Inc.
Date: Sept. 9, 2025 · CIK: 0001822791 · Accession: 0000000000-25-009769

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-290075

Date
September 9, 2025
Author
Division of
Form
UPLOAD
Company
Clene Inc.

Letter

Re: Clene Inc. Registration Statement on Form S-3 Filed September 5, 2025 File No. 333-290075 Dear Robert Etherington:

September 9, 2025

Robert Etherington President and Chief Executive Officer Clene Inc. 6550 South Millrock Drive, Suite G50 Salt Lake City, Utah 84121

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Chris Edwards at 202-551-6761 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Tom McAleavey

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 September 9, 2025

Robert Etherington
President and Chief Executive Officer
Clene Inc.
6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

 Re: Clene Inc.
 Registration Statement on Form S-3
 Filed September 5, 2025
 File No. 333-290075
Dear Robert Etherington:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Chris Edwards at 202-551-6761 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Tom McAleavey
</TEXT>
</DOCUMENT>